Your browser doesn't support javascript.
loading
Aggressive Subsets of Metastatic Triple Negative Breast Cancer.
Singh, Jasneet; Asad, Sarah; Zhang, Yiqing; Nock, William; Adams, Elizabeth; Damicis, Adrienne; Ramaswamy, Bhuvaneswari; Williams, Nicole; Parsons, Heather A; Adalsteinsson, Viktor A; Winer, Eric P; Lin, Nancy U; Partridge, Ann H; Overmoyer, Beth; Stover, Daniel G.
Afiliação
  • Singh J; Department of Medicine, Ohio State University College of Medicine, Columbus, OH.
  • Asad S; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Zhang Y; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Nock W; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Adams E; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Damicis A; College of Public Health, Division of Biostatistics, Ohio State University, Columbus, OH.
  • Ramaswamy B; Department of Medicine, Ohio State University College of Medicine, Columbus, OH; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Williams N; Department of Medicine, Ohio State University College of Medicine, Columbus, OH; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Parsons HA; Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Adalsteinsson VA; Blood Biopsy Team, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Winer EP; Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Lin NU; Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Partridge AH; Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Overmoyer B; Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Stover DG; Department of Medicine, Ohio State University College of Medicine, Columbus, OH; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH. Electronic address: daniel.stover@osumc.edu.
Clin Breast Cancer ; 20(1): e20-e26, 2020 02.
Article em En | MEDLINE | ID: mdl-31631016
ABSTRACT

BACKGROUND:

Relative to other metastatic breast cancer subtypes, metastatic triple-negative breast cancer (mTNBC) has a shorter duration of response to therapy and worse overall survival. Among patients with mTNBC, it is hypothesized that inflammatory breast cancer (IBC) and young women have particularly aggressive phenotypes. We investigated clinical and cell-free DNA (cfDNA) characteristics of inflammatory-mTNBC and young-mTNBC. PATIENTS AND

METHODS:

We evaluated 158 patients with mTNBC who were stratified into 3 groups (1) IBC; (2) patients aged 45 years or younger at primary diagnosis without IBC (non-IBC young); and (3) patients over age 45 at diagnosis without IBC. We evaluated clinicopathologic characteristics, sites of metastasis, survival outcomes, and the fraction of DNA in circulation derived from tumor (TFx).

RESULTS:

Analysis of metastatic sites revealed that young patients without IBC had the most frequent lung metastases (P = .002). cfDNA analyses of first sample showed that TFx was highest in the non-IBC young group but not elevated in the IBC group (analysis of variance P = .056 for first TFx). Individually, median overall survival from metastatic diagnosis for the IBC group was 15.2 months; for the non-IBC young group, 21.2 months, and for the non-IBC over 45 group, 31.2 months. Patients with IBC and young patients without IBC had worse prognosis relative to patients over 45 without IBC (log-rank P = .023).

CONCLUSIONS:

Among patients with mTNBC in this single-institution cohort, patients with IBC and young patients without IBC had significantly worse overall survival compared with patients over 45 without IBC. Young patients without IBC had significantly higher cfDNA TFx, whereas patients with IBC did not have elevated TFx despite a poor prognosis. These findings demonstrate that further analyses of mTNBC subsets are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Inflamatórias Mamárias / Neoplasias de Mama Triplo Negativas / Ácidos Nucleicos Livres Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Inflamatórias Mamárias / Neoplasias de Mama Triplo Negativas / Ácidos Nucleicos Livres Idioma: En Ano de publicação: 2020 Tipo de documento: Article